ERYTHROMYCIN-RESISTANT STAPH FOUND IN 74.4% OF CULTURES
This article was originally published in The Tan Sheet
Executive Summary
ERYTHROMYCIN-RESISTANT STAPH FOUND IN 74.4% OF CULTURES from treated patients in a study of 2% topical erythromycin conducted by Procter & Gamble to support a potential OTC switch for the treatment of acne. Presenting the data at a joint meeting of FDA's Dermatologic & Ophthalmic Drugs, Anti-Infective Drugs and Nonprescription Drugs Advisory Committees on Nov. 16, P&G said that 28.4% cultures from untreated patients showed bacterial strains resistant to erythromycin. A total of 830 strains of Staphylococci were isolated from treated and untreated patients, of which 50.4% were determined to be erythromycin-resistant.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning